(Q35868424)

10 August 2017

1 reference

title

The impact of fragility fracture on health-related quality of life : the importance of antifracture therapy (English)

1 reference

10 August 2017

1 reference

Ted Xenodemetropoulos

1

1 reference

10 August 2017

Shawn Davison

2

1 reference

10 August 2017

George Ioannidis

3

1 reference

10 August 2017

Jonathan D Adachi

4

1 reference

10 August 2017

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

21

1 reference

10 August 2017

11

1 reference

10 August 2017

711-730

1 reference

https://scigraph.springernature.com/pub.10.2165/00002512-200421110-00002

10 August 2017

0 references

cites work

The reliability and validity of the Turkish version of Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO).

1 reference

12 December 2020

EQ-5D: a measure of health status from the EuroQol Group

1 reference

12 December 2020

Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study

1 reference

12 December 2020

Function ten years after Colles' fracture.

1 reference

12 December 2020

Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group.

1 reference

12 December 2020

Users' guides to the medical literature. XII. How to use articles about health-related quality of life. Evidence-Based Medicine Working Group.

1 reference

12 December 2020

Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis

1 reference

12 December 2020

Risk Factors for Proximal Humerus, Forearm, and Wrist Fractures in Elderly Men and Women The Dubbo Osteoporosis Epidemiology Study

1 reference

12 December 2020

Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study.

1 reference

12 December 2020

Functional recovery after fractures of the distal forearm. Analysis of radiographic and other factors affecting the outcome

1 reference

12 December 2020

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group

1 reference

12 December 2020

The factor structure of the SF-36 Health Survey in 10 countries: results from the IQOLA Project. International Quality of Life Assessment.

1 reference

12 December 2020

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis

1 reference

12 December 2020

Postal administration compared with nurse-supported administration of the QUALEFFO-41 in a population sample: comparison of results and assessment of psychometric properties

1 reference

12 December 2020

The burden of osteoporotic fractures: a method for setting intervention thresholds

1 reference

12 December 2020

The clinical impact of vertebral fractures: quality of life in women with osteoporosis

1 reference

12 December 2020

A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture.

1 reference

12 December 2020

Gastric and duodenal safety of daily alendronate

1 reference

12 December 2020

Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis

1 reference

12 December 2020

Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures

1 reference

12 December 2020

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

1 reference

12 December 2020

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

12 December 2020

Quality of life related to fear of falling and hip fracture in older women: a time trade off study

1 reference

12 December 2020

The Influence of Osteoporotic Fractures on Health-Related Quality of Life in Community-Dwelling Men and Women across Canada

1 reference

12 December 2020

Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.

1 reference

12 December 2020

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

1 reference

12 December 2020

Has the impact of hormone replacement therapy on health-related quality of life been undervalued?

1 reference

12 December 2020

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group

1 reference

12 December 2020

Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial

1 reference

12 December 2020

The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial

1 reference

12 December 2020

The impact of osteoporosis on quality-of-life: the OFELY cohort.

1 reference

12 December 2020

A model of lifetime osteoporosis impact.

1 reference

12 December 2020

An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae

1 reference

12 December 2020

Long-term prognosis of displaced Colles' fracture: a 10-year prospective review.

1 reference

12 December 2020

The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women

1 reference

12 December 2020

Osteoporosis prevention, diagnosis, and therapy

1 reference

12 December 2020

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

12 December 2020

Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review

1 reference

12 December 2020

Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study

1 reference

12 December 2020

The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study

1 reference

12 December 2020

Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis.

1 reference

12 December 2020

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

1 reference

12 December 2020

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

12 December 2020

Reliability of an Osteoporosis-Targeted Quality of Life Survey Instrument for use in the community: OPTQoL.

1 reference

12 December 2020

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

1 reference

12 December 2020

General management of vertebral fractures

1 reference

12 December 2020

Circulating Insulin-Like Growth Factor System Changes in Women with Acute Estrogen Deficiency Induced by GnRH Agonist

1 reference

12 December 2020

1 reference

12 December 2020

Quality-of-life assessment in osteoporosis: health-status and preference-based measures.

1 reference

12 December 2020

Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study

1 reference

12 December 2020

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

12 December 2020

Use of cyclical etidronate and prevention of non-vertebral fractures.

1 reference

12 December 2020

1 reference

12 December 2020

Recovery of Function After Hip Fracture The Role of Social Supports

1 reference

12 December 2020

Measuring quality of life in women with vertebral fractures due to osteoporosis: a comparison of the OQLQ and QUALEFFO.

1 reference

12 December 2020

Development and validation of a specific quality of life module in post-menopausal women with osteoporosis: the QUALIOST.

1 reference

12 December 2020

Cyclical etidronate use is not associated with symptoms of peptic ulcer disease

1 reference

12 December 2020

Deterioration in quality of life following hip fracture: a prospective study

1 reference

12 December 2020

1 reference

12 December 2020

Risk of new vertebral fracture in the year following a fracture

1 reference

12 December 2020

Recommendations for the registration of new chemical entities used in the prevention and treatment of osteoporosis

1 reference

12 December 2020

Predictors of functional recovery one year following hospital discharge for hip fracture: a prospective study

1 reference

12 December 2020

Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women

1 reference

12 December 2020

Tolerability of risedronate in postmenopausal women intolerant of alendronate

1 reference

12 December 2020

Evaluation of physical capacity and quality of life in osteoporotic women.

1 reference

12 December 2020

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

1 reference

12 December 2020

Late physical and functional effects of osteoporotic fracture in women: the Rancho Bernardo Study.

1 reference

12 December 2020

14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status

1 reference

12 December 2020

Time since vertebral fracture: an important variable concerning quality of life in patients with postmenopausal osteoporosis

1 reference

12 December 2020

Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989

1 reference

12 December 2020

Sex steroids and bone: current perspectives

1 reference

12 December 2020

1 reference

12 December 2020

Molecular determinants of tissue selectivity in estrogen receptor modulators

1 reference

12 December 2020

Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women.

1 reference

12 December 2020

Development and validation of the mini-osteoporosis quality of life questionnaire (OQLQ) in osteoporotic women with back pain due to vertebral fractures. Osteoporosis Quality of Life Study Group.

1 reference

12 December 2020

Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system

1 reference

12 December 2020

[Pain, functional level and emotional problems of women with osteoporosis and vertebral fractures]

1 reference

12 December 2020

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

12 December 2020

Postmarketing surveillance of the safety of cyclic etidronate.

1 reference

12 December 2020

A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss

1 reference

12 December 2020

Increasing incidence of tibia condyle and patella fractures

1 reference

12 December 2020

Measurement of quality of life in rehabilitation medicine: Emerging issues

1 reference

12 December 2020

Costs and health effects of osteoporotic fractures.

1 reference

12 December 2020

Functional treatment of Colles fracture.

1 reference

12 December 2020

Development and validation of a discriminative quality of life questionnaire for osteoporosis (the OPTQoL).

1 reference

12 December 2020

Esophagitis and alendronate

1 reference

12 December 2020

The association of radiographically detected vertebral fractures with back pain and function: a prospective study

1 reference

12 December 2020

Diagnosis and management of vertebral fractures in elderly adults

1 reference

12 December 2020

Perspective. How many women have osteoporosis?

1 reference

12 December 2020

1 reference

12 December 2020

Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium

1 reference

12 December 2020

The Health Utilities Index (HUI): concepts, measurement properties and applications

1 reference

12 December 2020

Bisphosphonates: from the laboratory to the clinic and back again

1 reference

12 December 2020

Functional results after treatment of hip fracture: a multicentre, prospective study in 215 patients

1 reference

12 December 2020

Impact of hip and vertebral fractures on quality-adjusted life years.

1 reference

12 December 2020

Incidence of pelvic fractures in Finland in 1988

1 reference

12 December 2020

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

12 December 2020

A questionnaire to evaluate disability in osteoporotic patients with vertebral compression fractures

1 reference

12 December 2020

Epidemiologic features of humeral fractures

1 reference

12 December 2020

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

1 reference

12 December 2020

Quality of life in the economic evaluation of osteoporosis prevention and treatment

1 reference

12 December 2020

Responsiveness of the EuroQol (EQ 5-D) and the SF-36 in elderly patients with displaced femoral neck fractures.

1 reference

12 December 2020

2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.

1 reference

12 December 2020

Effects of estrogen plus progestin on health-related quality of life

1 reference

12 December 2020

Reliability of the Health Utilities Index--Mark III used in the 1991 cycle 6 Canadian General Social Survey Health Questionnaire.

1 reference

12 December 2020

Use of the SF-36 and other health-related quality of life measures to assess persons with disabilities

1 reference

12 December 2020

The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study

1 reference

12 December 2020

A systematic review of health state utility values for osteoporosis-related conditions

1 reference

12 December 2020

Epidemiology and predictors of fractures associated with osteoporosis

1 reference

12 December 2020

Foundations of Cost-Effectiveness Analysis for Health and Medical Practices

1 reference

12 December 2020

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

1 reference

12 December 2020

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling

1 reference

12 December 2020

Guidelines for clinical trials in osteoporosis. A position paper of the European Foundation for Osteoporosis and Bone Disease

1 reference

12 December 2020

Long-term results of conservative treatment of fractures of the distal radius

1 reference

12 December 2020

Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group

1 reference

12 December 2020

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

12 December 2020

Quality of life measurement in osteoporosis

1 reference

12 December 2020

Decline in physical function following hip fracture

1 reference

12 December 2020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials

1 reference

12 December 2020

Vertebral fracture and other predictors of physical impairment and health care utilization

1 reference

12 December 2020

Quality of life in osteoporosis: reliability, consistency, and validity of the Osteoporosis Assessment Questionnaire.

1 reference

12 December 2020

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years

1 reference

12 December 2020

Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women

1 reference

12 December 2020

Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation

1 reference

12 December 2020

Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials

1 reference

12 December 2020

Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

12 December 2020

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

12 December 2020

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

12 December 2020

1 reference

12 December 2020

Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials

1 reference

12 December 2020

Role of alendronate and risedronate in preventing and treating osteoporosis.

1 reference

12 December 2020

Quality of life in osteoporosis.

1 reference

12 December 2020

Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial

1 reference

12 December 2020

The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women.

1 reference

12 December 2020

Prevention and treatment of postmenopausal osteoporosis

1 reference

12 December 2020

The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos)

1 reference

12 December 2020

Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes

1 reference

12 December 2020

Quality of life issues in women with vertebral fractures due to osteoporosis.

1 reference

12 December 2020

Vertebral deformities and functional impairment in men and women

1 reference

12 December 2020

Adverse events reported by postmenopausal women in controlled trials with raloxifene

1 reference

12 December 2020

Efficacy of home-based exercise for improving quality of life among elderly women with symptomatic osteoporosis-related vertebral fractures

1 reference

12 December 2020

Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience

1 reference

12 December 2020

Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures

1 reference

12 December 2020

Cost-effective treatment strategies for osteoporosis

1 reference

12 December 2020

10.2165/00002512-200421110-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

10 August 2017

0 references

1 reference